T cell recognition of naturally expressed TCR V gene determinants represents an important regulatory mechanism for inhibiting T cell-mediated inflammatory responses and autoimmune diseases. In theory, anti-TCR response occurs during the formation of the T cell repertoire and involves T cell display of MHC-associated V gene epitopes. Thereafter, expansion of inflammatory T cells would lead to a coordinate activation of TCR-reactive Th2 cells that would eventually limit the Thl cell response and return the system to equilibrium. Our studies have demonstrated that vaccination of multiple sclerosis (MS) patients with TCR CDR2 peptides expressed by neuroantigen-specific Thl cells can rapidly boost anti-TCR Th2 responses in about half of the injected patients, with an associated decrease in response to the neuroantigen and a possible clinical benefit. However, a basic understanding of T-T network interactions is still lacking. In preliminary studies using the ELISPOT assay, the investigators observed that healthy donors had a substantial frequency (200-500 cells/million blood cells) of IL 10 producing Th2 cells specific for CDR2 peptides. In contrast, half of the MS patients had decreased responses (0-31 cells/million blood cells). Taken together, these data suggest that MS patients have a selective regulatory defect that might allow expansion of pathogenic T cells. The investigators' general hypothesis is that human anti-TCR reactive Th2 cells can regulate both target and bystander Thl cells by recognition of TCR determinants of the cognate V gene and release of inhibitory cytokines. The lack of TCR-specific Th2 cells in some MS patients could explain observed V gene bias by allowing selective expansion of Thl cells expressing unregulated V genes, including potentially pathogenic myelin-reactive T cells.
The specific aims of this proposal will 1) define naturally processed and expressed TCR determinants recognized by regulatory Th2 cells, 2) investigate the mechanism by which TCR reactive T cells regulate target and bystander Thl cells, and 3) evaluate the degree and extent of the defective Th2 response to recombinant TCR proteins and peptides in MS patients and controls, and relate decreased anti-TCR response to oligoclonal expansions of activated Thl cells. This proposal represents an important first step to define the molecular basis for natural T-T network interactions, and the information obtained will be crucial for understanding how TCR peptide vaccination affects this basic regulatory mechanism in the context of a putative Thl-mediated inflammatory disease. Conceivably, successful vaccination with TCR peptides affects mainly those MS patients with defective anti-TCR T cell frequencies by boosting regulatory Th2 responses. The approach outlined in this proposal thus has the potential to define the set of TCR determinants needed to restore deficient regulatory responses in each patient.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
2R01NS023221-14
Application #
6131101
Study Section
Special Emphasis Panel (ZRG1-EI (01))
Program Officer
Kerza-Kwiatecki, a P
Project Start
1986-08-01
Project End
2005-02-28
Budget Start
2000-03-01
Budget End
2001-02-28
Support Year
14
Fiscal Year
2000
Total Cost
$377,500
Indirect Cost
Name
Oregon Health and Science University
Department
Neurology
Type
Schools of Medicine
DUNS #
009584210
City
Portland
State
OR
Country
United States
Zip Code
97239
Buenafe, Abigail C; Andrew, Shayne; Offner, Halina et al. (2012) Regulatory T cells play a role in T-cell receptor CDR2 peptide regulation of experimental autoimmune encephalomyelitis. Immunology 135:168-79
Buenafe, Abigail C; Andrew, Shayne; Afentoulis, Michael et al. (2010) Prevention and treatment of experimental autoimmune encephalomyelitis with clonotypic CDR3 peptides: CD4(+) Foxp3(+) T-regulatory cells suppress interleukin-2-dependent expansion of myelin basic protein-specific T cells. Immunology 130:114-24
Wang, Chunhe; Dehghani, Babak; Li, Yuexin et al. (2009) Oestrogen modulates experimental autoimmune encephalomyelitis and interleukin-17 production via programmed death 1. Immunology 126:329-35
Vandenbark, Arthur A; Offner, Halina (2008) Critical evaluation of regulatory T cells in autoimmunity: are the most potent regulatory specificities being ignored? Immunology 125:1-13
Vandenbark, Arthur A; Abulafia-Lapid, Rivka (2008) Autologous T-cell vaccination for multiple sclerosis: a perspective on progress. BioDrugs 22:265-73
Sinha, Sushmita; Kaler, Laurie J; Proctor, Thomas M et al. (2008) IL-13-mediated gender difference in susceptibility to autoimmune encephalomyelitis. J Immunol 180:2679-85
Vandenbark, Arthur A; Culbertson, Nicole E; Bartholomew, Richard M et al. (2008) Therapeutic vaccination with a trivalent T-cell receptor (TCR) peptide vaccine restores deficient FoxP3 expression and TCR recognition in subjects with multiple sclerosis. Immunology 123:66-78
Imam, Sarah A; Guyton, Mary K; Haque, Azizul et al. (2007) Increased calpain correlates with Th1 cytokine profile in PBMCs from MS patients. J Neuroimmunol 190:139-45
Huan, Jianya; Culbertson, Nicole; Spencer, Leslie et al. (2005) Decreased FOXP3 levels in multiple sclerosis patients. J Neurosci Res 81:45-52
Matejuk, Agata; Hopke, Corwyn; Vandenbark, Arthur A et al. (2005) Middle-age male mice have increased severity of experimental autoimmune encephalomyelitis and are unresponsive to testosterone therapy. J Immunol 174:2387-95

Showing the most recent 10 out of 136 publications